Specialty pharmaceuticals company Cumberland Pharmaceuticals has invested $4 million in Talicia, the global product developed by biopharmaceutical company RedHill Biopharma. Talicia is the number one branded US gastroenterologist-prescribed H. pylori therapy, listed as a first-line H. pylori therapy in American College of Gastroenterology Clinical Guidelines. It remains the only FDA-approved all-in-one, low-dose rifabutin-based H. pylori therapy addressing antibiotic resistance. The strategic partnership […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!